A team at KAIST has built a drug that stays largely inert until it meets hydrogen peroxide, a reactive oxygen species that builds up in the brains of people with Alzheimer's disease. Because those elevated levels are concentrated in diseased tissue, the compound is meant to convert into its active form mainly where the damage is, rather than acting throughout the body. In animal experiments, the researchers reported improvements in cognitive function.
The work, announced by KAIST on the 2nd, came from a group led by Professor Mi Hee Lim of the Department of Chemistry, working with Professor Mingeun Kim of Chonnam National University, Dr. Chul-Ho Lee and Dr. Kyoung-Shim Kim of the Korea Research Institute of Bioscience and Biotechnology, and Dr. Young-Ho Lee of the Korea Basic Science Institute. Their compound is a prodrug: a molecule with little therapeutic activity of its own that becomes an active drug only under specific biological conditions.
What makes the design unusual is the reframing of hydrogen peroxide itself. It has generally been treated as a harmful byproduct to be cleared away in neurodegenerative disease. Here, the excess is repurposed as a chemical address label, a signal that tells the drug where and when to switch on. In principle, that kind of selectivity is what researchers chase to reduce effects on healthy tissue, a persistent problem for drugs aimed at the brain.
The findings so far come from animal models, which is a long way from showing benefit in people, and the path from a promising prodrug design to a tested therapy is a slow one. The value of this study lies less in an immediate treatment than in the strategy: using a marker of disease as the trigger for its own treatment is an approach that could be applied to other targets in dementia research.